Dr Florian Markowetz awarded a CRUK Future Leaders Prize

Dr Florian Markowetz was one of three researchers awarded a Cancer Research UK Future Leaders in Cancer Research Prize at an awards ceremony at the National Cancer Research Institute (NCRI) Cancer Conference.
This prize recognises scientists early in their career whose significant contribution to cancer research demonstrates their potential to become world-class leaders in their field.
Dr Florian Markowetz’s work is providing insights into how tumours interact with their environment. By studying the cancer’s genes in the context of the tissue around it, they are finding which signals indicate how a cancer will behave. You can find out more about his work here.
Sir Harpal Kumar, chief executive of Cancer Research UK, said: “I’m delighted to announce this year’s prize winners. These pioneering scientists are receiving awards for their extraordinary and wide-ranging contributions to cancer research. Although their work spans many different areas and types of cancer, they all share a determination to beat cancer for good. Through their pioneering work they open up new opportunities to detect and treat cancer which will help us save lives.”
Related News
See all news-
Sir Shankar Balasubramanian elected Fellow of the AACR Academy
10th March 2025
Sir Shankar has been recognised for his pioneering research in nucleic acid chemistry and his key role in the development of next-generation sequencing technology.
Find out more -
Richard Mair joins Institute as an Independent Clinical Fellow
10th February 2025
Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, , a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Find out more -
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
6th December 2024
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more